Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Sexual function and combi… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Sexual function and combined oral contraceptives: a randomised, placebo-controlled trial

Artikel i vetenskaplig tidskrift
Författare C. Lundin
A. Malmborg
J. Slezak
K. G. Danielsson
M. Bixo
H. Bengtsdotter
L. Marions
Ingela Lindh
E. Theodorsson
M. Hammar
I. Sundstrom-Poromaa
Publicerad i Endocrine Connections
Volym 7
Nummer/häfte 11
Sidor 1208-1216
ISSN 2049-3614
Publiceringsår 2018
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi
Sidor 1208-1216
Språk en
Länkar dx.doi.org/10.1530/ec-18-0384
Ämnesord combined oral contraceptive, McCoy Female Sexuality Questionnaire, placebo, randomised clinical, a double-blind, steroid-hormones, women, mood, improvement, cortisol, quality, desire, hair, life
Ämneskategorier Obstetrik och kvinnosjukdomar, Endokrinologi

Sammanfattning

Objective: The effect of combined oral contraceptives (COCs) on female sexuality has long been a matter of discussion, but placebo-controlled studies are lacking. Thus, the aim of the present study was to investigate if an oestradiol-containing COC influences sexual function. Design: Investigator-initiated, randomised, double-blinded, placebo-controlled clinical trial where 202 healthy women were randomised to a combined oral contraceptive (1.5 mg oestradiol and 2.5 mg nomegestrol acetate) or placebo for three treatment cycles. Methods: Sexual function at baseline and during the last week of the final treatment cycle was evaluated by the McCoy Female Sexuality Questionnaire. Serum and hair testosterone levels were assessed at the same time points. Results: Compared to placebo, COC use was associated with a small decrease in sexual interest (COC median change score: -2.0; interquartile range (IQR): -5.0 to 0.5 vs placebo: -1.0; IQR: -3.0 to 2.0, P=0.019), which remained following adjustment for change in self-rated depressive symptoms (B= -0.80 +/- 0.30, Wald =7.08, P=0.008). However, the proportion of women who reported a clinically relevant deterioration in sexual interest did not differ between COC or placebo users (COC 18 (22.2%) vs placebo 16 (17.8%), P=0.47). Change in other measured aspects of sexual function as well as total score of sexual function did not differ between the two treatments. Conclusions: This study suggests that use of oestradiol-based COCs is associated with reduced sexual interest. However, the changes are minute, and probably not of clinical relevance.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?